5.3.1 HIV infection

Nucleoside reverse transcriptase inhibitors

MHRA Drug safety Update July 2009: Abacavir-containing medicines should be used in line with current treatment guidelines and with caution in patients with high cardiovascular risk factors. Action should be taken to minimise all modifiable risk factors (e.g. smoking, high blood pressure, hyperlipidaemia, and diabetes).

Tenofovir disoproxil
  • Tablets 245mg
  • Granules 33mg/g

Notes

  1. NICE TA173 - Tenofovir disoproxil for the treatment of chronic hepatitis B (July 2009)

Non-nucleoside reverse transcriptase inhibitors

Doravirine
  • Tablets 100mg

Notes

  1. For use in line with the NHS England Clinical Commissioning Policy (November 2019)

 

Home > Formulary > Chapters > 5. Infections > 5.3 Antiviral drugs > 5.3.1 HIV infection

 

  • First line
  • Second line
  • Specialist
  • Hospital